Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.54 |
| ▸ | RAB9A | P51151 | 8/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4772163 | 0.94 | NPC1 (0.57) | NPC1RAB9APKMHRH3MAPT | |
| Trifluoroacetic Acid SCHEMBL4771045 | 0.89 | RAB9A (0.53) | NPC1RAB9APKMSLC2A1 | |
| SCHEMBL4768108 | 0.86 | NPC1 (0.51) | NPC1RAB9APKMHRH3MAPT | |
| SCHEMBL4774462 | 0.86 | RAB9A (0.59) | NPC1RAB9APKM | |
| Hydrochloric Acid SCHEMBL4776625 | 0.85 | NPC1 (0.50) | NPC1RAB9APKMHRH3MAPT | |
| SCHEMBL4765305 | 0.84 | RAB9A (0.48) | NPC1RAB9APKMHRH3P2RY12 | |
| Hydrochloric Acid SCHEMBL4774495 | 0.84 | RAB9A (0.47) | NPC1RAB9APKMHRH3P2RY12 | |
| Trifluoroacetic Acid SCHEMBL4767946 | 0.83 | HRH3 (0.56) | NPC1RAB9AHRH3MAPTTP53 | |
| Trifluoroacetic Acid SCHEMBL4765179 | 0.81 | SLC2A1 (0.44) | HRH3MAPTTP53THRBSLC2A1 | |
| Trifluoroacetic Acid SCHEMBL4765164 | 0.80 | MAPT (0.49) | HRH3MAPTTP53THRBSLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | claimed |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | claimed |
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | HRH3, HRH4, HRH1 | NPC1 2009/4885RAB9A 2307/4885PKM 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.